Compare Enphase Energy Inc (ENPH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Enphase Energy Inc trades at $32.12 (market cap $4.35B), while Vertex Pharmaceuticals Incorporated trades at $510.9 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 29.3× Enphase Energy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ENPH | VRTX | |
|---|---|---|
Market Cap | $4.35B | $127.55B |
Volume | 5,068,595 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $72.33 | $557.96 |
52-Week Low | $26.12 | $407.37 |
Typical Hold Time | 72 Days | 120 Days |
Enterprise Value | $3.99B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.095, down 4.19% with bearish technical signals. The stock shows mixed fundamentals with revenue declining from $2.3B in 2023 to $1.47B in 2025, though net income margin improved to 11.68%. Recent earnings show two misses in the last three quarters. Analyst sentiment is divided with 42% buy ratings but a consensus price target of $42.90 suggesting 34% upside. The company continues innovation with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
The stock faces headwinds from solar industry pressures and elevated borrowing costs, but maintains strong gross margins and product innovation. With current price near support at $32 and significant upside to analyst targets, ENPH presents a contrarian opportunity for investors believing in the long-term solar growth story despite near-term volatility.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
